

lt's Wholecare.

Updated: 05/2020 PARP Approved: 06/2020

Prior Authorization Criteria Luxturna (voretigene neparvovec-rzyl)

All requests for Luxturna (voretigene neparvovec-rzyl) require a prior authorization and will be screened for medical necessity and appropriateness using the criteria listed below.

Coverage may be provided with a <u>diagnosis</u> of biallelic *RPE65* mutation-associated retinal dystrophy and the following criteria is met:

- The member must be at least 1 year old
- Must have a diagnosis of retinal dystrophy with confirmed RPE65 mutation in both alleles
- Must be prescribed by or in consultation with an ophthalmologist
- Must have viable retinal cells as determined by the treating physician
- The requested dose and frequency is in accordance with FDA-approved labeling, nationally recognized compendia, and/or evidence-based practice guidelines
- **Initial Duration of Approval:** 1 injection per eye (1 month)
- Reauthorization criteria
 - o None one time use

Coverage may be provided for any non-FDA labeled indication if it is determined that the use is a medically accepted indication supported by nationally recognized pharmacy compendia or peer-reviewed medical literature for treatment of the diagnosis(es) for which it is prescribed. These requests will be reviewed on a case by case basis to determine medical necessity.

When criteria are not met, the request will be forwarded to a Medical Director for review. The physician reviewer must override criteria when, in their professional judgment, the requested medication is medically necessary.



It's Wholecare.

Updated: 05/2020 PARP Approved: 06/2020

LUXTURNA PRIOR AUTHORIZATION FORM

Please complete and fax all requested information below including any progress notes, laboratory test results, or chart documentation as applicable to Gateway HealthSM Pharmacy Services. **FAX:** (888) 245-2049

If needed, you may call to speak to a Pharmacy Services Representative

	NE : (800) 392-1147 Monda			
11101		INFORMATION	ani to 5.00pm	
Requesting Provider:	IKOVIDEKI	NPI:		
		= 1= =1	ffice Contact:	
Office Address:		Office Phone:		
Office Hadress.		Office Fax		
MEMBER INFORMATION				
Member Name:		DOB:		
Gateway ID:		Member weight:	pounds or kg	
REQUESTED DRUG INFORMATION				
Medication:	REQUESTED DR	Strength:		
Directions:		Quantity: Refi		
Is the member currently receiving in	requested medication?		Medication Initiated:	
Billing Information				
This medication will be billed: at a pharmacy OR				
medically (if medically please provide a JCODE:				
Place of Service: Hospital		ember's home Othe		
Place of Service Information				
Name:	NPI:			
Address:		Phone:		
MEDICAL HISTORY (Complete for ALL requests)				
Diagnosis:				
Retinal Dystrophy				
Other: ICD-10 Code:				
Does the member have confirmed RPE65 mutation in both alleles? Yes No				
Which eye is being treated? Left Right Both				
Does the member have viable retinal cells? Yes No				
CURRENT or PREVIOUS THERAPY				
Medication Name	Strength/ Frequency	Dates of Therapy	Status (Discontinued & Why/Current)	
1/10th cutton 1 (unite	Strongen Trequency	Duttes of Therapy		
SUP	PORTING INFORMATI	ON or CLINICAL R	ATIONALE	
		OIV OF CERVICIER		
Prescribing Provide	er Signature		Date	
	(-)			